Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study

• المؤلفون الرئيسيون: Lina Renkhold (مؤلف), Manuel P. Pereira (مؤلف), Karin Loser (مؤلف), Dieter Metze (مؤلف), Daniel Baeumer (مؤلف), Nima Melzer (مؤلف), Maximilian Reinhardt (مؤلف), Athanasios Tsianakas (مؤلف), Thomas Luger (مؤلف), Christian Mess (مؤلف), Ruth Becker (مؤلف), Clara Hambüchen (مؤلف), Konstantin Agelopoulos (مؤلف), Sonja Ständer (مؤلف)
• التنسيق: كتاب
• منشور في: Medical Journals Sweden, 2024-11-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous neuroanatomy remained unknown. The primary objective of...